Higashiyama RI, Yoshida T. A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC. J Thorac Oncol 2024;19:e33-e34.
PMID: 39242142